The GH / IGF axis at a glance
Growth hormone (GH) is released from somatotroph cells of the anterior pituitary. Its secretion is regulated by two hypothalamic peptides acting on the somatotroph: GHRH, which stimulates GH release through the GHRH receptor, and somatostatin, which suppresses it. A third input comes through the ghrelin / GHS-R1a pathway, first characterised as a growth-hormone-releasing peptide (GHRP) receptor and later matched to its endogenous ligand, ghrelin.
Circulating GH acts on peripheral tissues in part by inducing hepatic synthesis of insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream effects and feeds back to modulate the axis. The pulsatile pattern of GH release in vivo is a key characteristic often preserved in preclinical models used to study secretagogue peptides.
CJC-1295 as a long-acting GHRH analog
CJC-1295 is derived from GHRH(1–29), a truncated but active fragment of native GHRH. It contains four amino-acid substitutions that block the primary sites of proteolytic degradation and, in the DAC (drug-affinity-complex) form, a maleimidopropionic-acid linker at the C-terminus that forms a stable thioether bond with a free cysteine on serum albumin. That covalent albumin binding extends the plasma half-life dramatically compared with unmodified GHRH.
In the research literature, CJC-1295 exists in two forms — with-DAC (long-acting) and no-DAC (shorter-acting, sometimes labelled 'Mod GRF 1-29'). The distinction matters when reading published work, because pharmacokinetics differ substantially between the two forms.
Ipamorelin as a selective GHRP
Ipamorelin is a synthetic pentapeptide developed as a selective agonist of the GHS-R1a receptor. In the original characterisation, it was distinguished from earlier GHRPs (GHRP-2, GHRP-6, hexarelin) by a cleaner secretagogue profile — potent GH release without the significant elevations in cortisol or prolactin that characterise less selective GHRPs.
Structurally, ipamorelin belongs to a class of small peptides and peptidomimetics that mimic the acyl-modified octanoyl group of ghrelin required for GHS-R1a activation, but achieves receptor engagement through a distinct backbone rather than reproducing ghrelin's fatty-acid modification.
Rationale for combined preclinical use
GHRH analogs and GHRPs stimulate somatotroph GH release through parallel intracellular pathways: GHRH via cAMP through the GHRH receptor, and GHRPs via phospholipase C and calcium mobilisation through GHS-R1a. The two signalling arms are synergistic in vitro and in vivo — combining a GHRH analog with a GHRP produces greater GH release than either alone.
This synergy is the standard rationale for pairing CJC-1295 with ipamorelin in preclinical research: the combination allows study of amplified but still physiologically-shaped GH pulses, in contrast to the sustained non-pulsatile elevation produced by exogenous GH itself.
Somatostatin tone and the pulsatile nature of GH release
The third input to somatotroph regulation — somatostatin — is central to why pulsatile GH release exists at all, and why secretagogue combinations preserve pulsatility while sustained exogenous GH does not. Somatostatin is released from hypothalamic neurons on a rhythm broadly antiphase to GHRH, producing alternating windows of stimulation and suppression on the somatotroph. The result is discrete GH pulses rather than a tonic circulating level.
GHRPs interact with this system in a way distinct from GHRH. In addition to directly stimulating GH release through GHS-R1a, GHRPs have been reported to attenuate somatostatin's suppressive tone at the somatotroph. That opens a longer permissive window in each pulse cycle and is one mechanistic explanation for the synergy observed when GHRH analogs and GHRPs are combined — the GHRP arm removes the brake while the GHRH arm applies the accelerator.
For preclinical experimental design, this framework has practical implications. Blood-sampling protocols that miss the pulse structure — sparse or single-timepoint sampling — will underestimate the difference between GHRH-only, GHRP-only, and combined administration. Well-designed studies use frequent sampling over an observation window sized to capture at least one full pulse cycle.
The pulsatile framework also matters when interpreting downstream endpoints. IGF-1, the peripheral mediator of many GH effects, integrates over hours to days and reflects average GH exposure — a smoothed proxy rather than a pulse-resolved measure. Comparing IGF-1 responses across secretagogue-combination arms is informative but should not be over-interpreted as a direct index of pulse amplitude.
Comparative context
In the GHRH-analog family, CJC-1295 sits alongside sermorelin (native GHRH 1-29, unmodified) and tesamorelin (a stabilised GHRH analog with different pharmacokinetics). Comparing these three illustrates how modifications to the same core sequence change half-life and receptor engagement duration.
In the GHRP family, ipamorelin sits alongside GHRP-2, GHRP-6, and hexarelin. Comparative preclinical work has focused on selectivity, cortisol and prolactin off-target effects, and receptor engagement kinetics. Ipamorelin's selectivity is its defining feature in that comparison.
Analytical characterisation
Both peptides are characterised by mass spectrometry for identity and reversed-phase HPLC for purity. Ipamorelin has a molecular weight near 712 Da; CJC-1295 (no DAC) is a 30-residue peptide near 3369 Da; the DAC form is larger owing to the C-terminal linker.
For the DAC form, quality assessment also considers the reactivity of the maleimidopropionic-acid moiety — its ability to form the intended thioether bond with albumin cysteine — which is best characterised alongside HPLC and MS on the intact peptide.
Reconstitution and storage
Both peptides are soluble in aqueous buffer and reconstituted with bacteriostatic or sterile water. As with any lyophilised peptide, gentle handling — no shaking, letting diluent run down the inside wall of the vial — protects material integrity.
Store lyophilised material sealed and cold, and aliquot reconstituted material into single-use portions to minimise freeze-thaw exposure. Both peptides are broadly stable under standard cold-chain conditions, but working-concentration solutions should be characterised in the specific buffer system used.
Worked examples
Reconstituting a 5 mg CJC-1295 (no DAC) vial
- 01Bring the sealed vial to room temperature before opening.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2 mL of bacteriostatic water for a nominal 2.5 mg/mL working concentration.
- 04Let diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved. Do not shake.
- 06Label with lot, concentration, diluent, and date.
Reconstituting a 5 mg ipamorelin vial
- 01Bring the vial to room temperature.
- 02Add 2.5 mL of bacteriostatic water for a nominal 2 mg/mL working concentration.
- 03Swirl gently until dissolved.
- 04Aliquot into single-use portions before freezing.
Frequently asked questions
What is the difference between CJC-1295 with DAC and no DAC?
The DAC form carries a maleimidopropionic-acid linker that binds covalently to serum albumin, giving a plasma half-life measured in days. The no-DAC form lacks that linker and is much shorter-acting — often called 'Mod GRF 1-29' in the research literature. Both are studied preclinically; pharmacokinetics differ substantially.
Why are CJC-1295 and ipamorelin often studied together?
They stimulate GH release through parallel intracellular pathways in the same somatotroph — CJC-1295 via GHRH-R / cAMP, ipamorelin via GHS-R1a / calcium — and the combination is synergistic in vitro and in vivo, allowing study of amplified but still physiologically-shaped GH pulses.
How does ipamorelin differ from GHRP-2 or GHRP-6?
Ipamorelin was characterised as a selective GHS-R1a agonist that stimulates GH release without the significant cortisol and prolactin elevations seen with less selective GHRPs. That selectivity is the defining feature of ipamorelin in comparative preclinical work.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity, and mass spectrometry confirms identity against the expected molecular weight — approximately 712 Da for ipamorelin and 3369 Da for CJC-1295 no-DAC. A batch COA should show a dominant single peak and the correct mass.
How should lyophilised material be stored?
Sealed and desiccated at 2–8 °C for short-term or −20 °C for longer-term storage. After reconstitution, refrigerate and aliquot into single-use portions to minimise freeze-thaw exposure.
References
Selected published research referenced in this article.
- 01Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed
- 02Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed
- 03Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PubMed
- 04Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. PubMed
- 05Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21–31. PubMed
- 06Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159. PubMed